Full Text View
Tabular View
Study Results
Related Studies
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548AM2)(COMPLETED)
This study has been completed.
Study NCT00302081   Information provided by Schering-Plough
First Received: March 10, 2006   Last Updated: June 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis C
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
peginterferon alfa-2b (SCH 54031)
ribavirin (SCH 18908)
Additional drug interventions recognized in this trial
Interferon Alfa-2b
Peginterferon alfa-2b
Ribavirin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Schering-Plough
Integrated Therapeutics Group


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services